Ibogaine for the Injured Brain: A New Model for Treatment - Jonathan Dickinson
Release Date: 03/16/2026
Why 5-MeO-DMT Doesn't Have to Be Explosive - Mira Funk, LCSW
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Mira Funk, LCSW, a Harvard-educated psychotherapist and the founder of , a private practice built around 5-MeO-DMT, N,N-DMT, and salvia divinorum. This episode is sponsored by Mira Funk. Mira traces her path from fourteen years of Zen meditation into psychedelic work, and explains how a severe reaction to a common nootropic supplement unexpectedly reoriented her entire practice toward presence rather than dramatic, otherworldly trips. She and Paul go deep on the extended-release routes she has pioneered, including...
info_outline
Why Medicalizing Psychedelics Is a Mistake - Dave Asprey
The Psychedelic Podcast
Paul talks with biohacking pioneer Dave Asprey about medicalization, microdosing, consciousness, and Dave's new BEYOND Wonderland psychedelics conference in Austin. In this bonus episode, Paul welcomes back Dave Asprey, founder of Bulletproof Coffee and creator of the biohacking movement, to talk about BEYOND Wonderland, the psychedelics conference Dave has revamped for October 12-14 in Austin. They also get into medicalization, the CIA's documented role in psychedelic history, what responsible microdosing regulation could look like, and why Dave is as focused on unlocking latent human ability...
info_outline
Psychedelics, AI, and the Right to Think - Ramez Naam
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with computer scientist, climate investor, and Nexus author Ramez Naam about psychedelics, AI, neurotechnology, and cognitive liberty. Find full show notes and links here: Ramez shares how psychedelic experiences sparked his interest in neuroscience, inspired his books, and helped redirect his work toward climate and clean energy. He and Paul explore what brain-computer interfaces can do today, the future of psychedelic mental healthcare, and how to protect freedom of thought as AI becomes a more personal tool. Ramez Naam is a...
info_outline
Psychedelic Therapy Needs More Than Good Intentions - Kylea Taylor, M.S., LMFT
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with therapist and InnerEthics® founder Kylea Taylor about why responsible psychedelic therapy requires more than good intentions. Find full show notes and links here: Kylea explains why non-ordinary states can amplify intimacy, vulnerability, countertransference, and practitioner blind spots. She presents ethics as an ongoing practice of self-inquiry, restraint, and right relationship rather than a set of rules consulted only after something goes wrong. Paul and Kylea also examine personal experience as preparation for...
info_outline
Iboga Initiation and the Wisdom of Discomfort - Paije Alexandra West
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Paije Alexandra West, founder of , about iboga, ibogaine, and Bwiti initiation. Drawing on Paul’s recent retreat experience at ETÉREO in Baja, they examine what can be lost when iboga is reduced to a clinical alkaloid and how traditional ceremony can coexist with rigorous medical screening. Paije explains the differences between iboga root bark and total alkaloid extract, the role of Bwiti music, and why discomfort, community, and long-term integration are central to working responsibly with this demanding medicine....
info_outline
SSRI Tapering and Psychedelic Readiness - Dr. Josef Witt-Doerring
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with psychiatrist and TaperClinic founder Dr. Josef Witt-Doerring about antidepressant withdrawal, psychiatric deprescribing, and psychedelic readiness. Find full show notes and links here: Josef explains what he learned reviewing drug safety at the FDA, why withdrawal can be mistaken for relapse, and how tapering often becomes more difficult at lower doses. They also explore the lifestyle foundations of mental health, benzodiazepine withdrawal, and why psychedelic clinics may need far more sophisticated support as increasingly...
info_outline
SSRIs, Psychedelics, & Rethinking Mental Health Treatment - Robert Whitaker
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with investigative journalist Robert Whitaker about the evidence behind psychiatric prescribing, SSRI withdrawal, and what psychedelic medicine can learn from that history. Find full show notes and links here: Whitaker revisits the chemical imbalance theory, long-term antidepressant outcomes, and how psychiatric drugs evolved from short-term interventions toward chronic use. He also explores the social and environmental dimensions of mental health before turning to psychedelic medicine and the risks of recreating a...
info_outline
Ketamine, SSRIs & the Future of Psychedelic Therapy - Dr. Remi Drozd
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Dr. Remi Drozd back to explore ketamine, SSRIs, and the changing landscape of psychedelic mental health care. Find full show notes and links here: Since Remi first appeared on the podcast in Episode 182, Lucid Therapeutics has grown from a small ketamine practice into a ten-room interventional mental health clinic offering ketamine treatments, Spravato, TMS, therapy, integration support, and other approaches. Paul and Remi examine one of the less-discussed challenges facing psychedelic medicine: many prospective patients are...
info_outline
Psychedelic Medicine’s Biggest Blind Spots - Dr. Richard Louis Miller
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Dr. Richard Louis Miller about what psychedelic medicine must get right as it moves toward broader acceptance. Richard explains why transparent reporting of adverse effects is essential to informed choice, where research still leaves important gaps, and how commercialization could shape access and treatment. They examine 5-MeO-DMT, group therapy, and the limits of one-to-one care. Richard also shares his approach to aging through exercise, real food, rest, and human connection. Dr. Richard Louis Miller is a clinical...
info_outline
Inside the World of Dark Retreats - Ian Gardner
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Ian Gardner, founder and CEO of , about dark retreats as an ancient contemplative practice now entering Western culture. This episode is sponsored by The Acraya. Listeners of The Psychedelic Podcast can receive 5% off an Acraya retreat. Visit and use discount code 3WAVE when booking. Ian explains what happens when external stimulation disappears, why boredom and difficult inner material can become central parts of the experience, and how dark retreats compare with psychedelics and extended meditation. He also discusses...
info_outlineIn this episode of The Psychedelic Podcast, Paul F. Austin speaks with Jonathan Dickinson, CEO and Co-Founder of Ambio Life Sciences, about the evolving role of ibogaine in psychedelic medicine.
Listen to the full episode: https://thethirdwave.co/podcast/episode-347/?ref=278
Jonathan shares his path from leading the Global Ibogaine Therapy Alliance to helping build one of the field’s most prominent ibogaine treatment organizations. Together they explore ibogaine’s expanding therapeutic potential for traumatic brain injury, addiction, and neurological conditions, along with the clinical realities of delivering this powerful medicine safely.
They also discuss the challenges of scaling ibogaine treatment, the importance of preparation and integration, and how traditional Bwiti knowledge from Gabon continues to shape ethical and culturally grounded approaches to this work.
Jonathan Dickinson is the CEO and Co-Founder of Ambio Life Sciences and a leading expert on ibogaine therapy. With more than 15 years of experience in psychedelic research, clinical care, and traditional practice, he has helped shape global safety standards for ibogaine treatment.
A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, Jonathan has published research on ibogaine’s therapeutic potential for trauma, traumatic brain injury, and neurological conditions. He has also been initiated into the Bwiti traditions of Gabon and holds a Nagoya-compliant export license for Tabernanthe iboga root.
Highlights:
- Jonathan Dickinson’s path from the Global Ibogaine Therapy Alliance to Ambio Life Sciences
- How ibogaine treatment expanded beyond opioid detox
- The growing use of ibogaine for traumatic brain injury and veterans’ recovery
- Why ibogaine treatment requires extensive medical screening and preparation
- The importance of integration and community support after treatment
- What Bwiti traditions in Gabon teach about working with iboga
- The challenges of scaling ibogaine treatment safely
- Why ibogaine may create a longer window for lasting change